HRT and the Endometrium

1. Coope J Marsh J. Can we improve compliance with long-term HRT. Maturitas 1992; 15: 151–158.

2. Barentsen R Groenvaeld F Bareman FP Hoes AW Dokler HJ Drogendjik AC . Women's opinion on withdrawal bleeding with hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 1993; 51: 203–207.

3. Hope S Rees M. Why do British women start and stop HRT? J Brit Meno Soc 1995; 1: 26–27.

4. Udoff Langenberg P Adashi EY . Combined continuous therapy: a critical review. Obstet Gynecol 1995; 86: 306–316.

5. Kaiserman-Abramof IR Padykula HA . Angiogenesis in the postovulatory primate endometrium: the coiled arteriolar system. Anatomical Record 1989; 224: 479–489.

6. Zhang L Reeds MCP Bicknell R. The isolation and long-term culture of normal human endometrial ephithelium and stroma. Expression of mRNAs for angiogenic polypeptides basally and on oestrogen and progesterone challenges. J Cell Science 1995; 108: 323–331.

7. Grady D Gebretsadik T Kerlikowske K Ernster V Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynaecol 1995; 85: 304–313.

8. Paterson MEL Wade-Evans T Sturdee DW Thorn MH Studd JWW . Endometrial disease after treatment with oestrogens and progestogens in the climacteric. Br Med J 1980; 280: 822–824.

9. Smith D Prentice R Thompson D Hermann W. Association of exogeneous estrogen and endometrial carcinoma. N Eng J Med 1975; 293: 1164–1167.

10. Gambrell RD . The prevention of endometrial cancer in postmenopausal women with progestogens. Maturitas 1978; 1: 99–106.

11. Voigt L . Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274–77.

12. Brinton L Hoover R. Estrogen replacement therapy and endometrial cancer: unresolved issues. Obstet Gynecol 1993; 81: 265–271.

13. Fox J Buckly CH . The endometrial hyperplasia and their relationship to endometrial neoplasia Histopathology 1982; 4: 493–510.

14. Kurman RJ Kaminski PF Norris HJ . The behaviour of endometrial hyperplasia. A long term study of untreated hyperplasia in 170 patients. Cancer 1985; 56: 403–412.

15. Archer DF . Endometrial morphology in asymptomatic premenopausal women. Am J Obstet Gynecol 1991; 65: 317–322.

16. Koss LG Schreiber K Oberland SG Moussouris HF Lesser M 1984. Detection of endometrial carcinoma and hyperplasia in asymptomatic women. Obstet Gynecol 1984; 64: 1–11.

17. Sturdee DW Barlow DH Wells M Ulrich LG Gydesen H Campbell M O'Brien K Vessey M. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestogen replacement therapy? Lancet 1994; 343: 979–982.

18. Ettinger B Selby J Citron J Vagessel A Ettinger VM Hendrickson MR 1994. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynaecol 1994; 83: 693–700.

19. Hirvonen E . Can progestin be limited to every third month only in postmenopausal women taking oestrogen? Maturitas 1995; 21, 39–44.

20. Woodruff JD Pickar JH . Incidence of endometrial hyperplasia in postmenopausal women taking conjugated oestrogens (Premarin) with medroxyprogesterone acetate or conjugated oestrogens alone. Am J Obstet Gynaecol 1994; 170: 1213–1223.

21. Leather AT Savvas M Studd JW . Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1991; 78: 1008–1010.